Back to Search
Start Over
Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage
- Source :
- Expert Opinion on Pharmacotherapy. 8:1733-1742
- Publication Year :
- 2007
- Publisher :
- Informa Healthcare, 2007.
-
Abstract
- Orlistat, in the 60-mg over-the-counter dose, was recently approved by the FDA. This lipase inhibitor blocks absorption of ~25% of ingested fat and has ~85% of the efficacy of the 120-mg dose for weight loss. Over 16 weeks weight loss with diet and orlistat 60 mg averages ~5% of initial body weight. The 60-mg dose is better tolerated than the 120-mg dose and the gastrointestinal side effects are minimal when individuals consume < 30% of their energy from fat. In addition to facilitating modest weight loss, orlistat use decreases serum LDL-cholesterol values by ~10%. When taken three times daily before meals, orlistat 60 mg modifies lifestyle behavior, encourages lower fat-consumption and sets the stage for other healthy lifestyle changes.
- Subjects :
- medicine.medical_specialty
Nonprescription Drugs
Overweight
Dosage form
Lactones
Weight loss
Internal medicine
medicine
Animals
Humans
Pharmacology (medical)
Obesity
Before Meals
Dosage Forms
Orlistat
Pharmacology
business.industry
Body Weight
General Medicine
medicine.disease
Endocrinology
Lipase inhibitors
Over-the-counter
medicine.symptom
business
medicine.drug
Subjects
Details
- ISSN :
- 17447666 and 14656566
- Volume :
- 8
- Database :
- OpenAIRE
- Journal :
- Expert Opinion on Pharmacotherapy
- Accession number :
- edsair.doi.dedup.....e3650fcccf3e727a56c7e8b32971f43d
- Full Text :
- https://doi.org/10.1517/14656566.8.11.1733